Abstract:You have accessJournal of UrologyProstate Cancer: Advanced (including Drug Therapy) II (MP24)1 Sep 2021MP24-11 LOCAL THERAPY TO THE PRIMARY TUMOR FOR NEWLY DIAGNOSED, OLIGO-METASTATIC PROSTATE CANCER: A PROSPECTIVE RANDOMIZED, PHASE 2, OPEN-LABEL TRIAL Bo Dai, Junyu Zhang, Sheng Zhang, Hongkai Wang, Qifeng Wang, Yunyi Kong, Yao Zhu, Xiaojian Qin, Guowen Lin, and Dingwei Ye Bo DaiBo Dai More articles by this author , Junyu ZhangJunyu Zhang More articles by this author , Sheng ZhangSheng Zhang More articles by this author , Hongkai WangHongkai Wang More articles by this author , Qifeng WangQifeng Wang More articles by this author , Yunyi KongYunyi Kong More articles by this author , Yao ZhuYao Zhu More articles by this author , Xiaojian QinXiaojian Qin More articles by this author , Guowen LinGuowen Lin More articles by this author , and Dingwei YeDingwei Ye More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002015.11AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Oligo-metastatic prostate cancer is recognized as an intermediate stage between localized disease and widespread metastases. The role of radical local therapy (RLT) to the primary tumor for these patients is unclear. We conducted this phase 2 randomized trial to investigate if radical prostatectomy (RP) or prostate radiotherapy (RT) benefits these patients (NCT02742675). METHODS: Oligo-metastases was defined as ≤5 bone or extra-pelvic lymph node metastases and no visceral metastases. Patients were randomly assigned (1:1) to receive androgen deprivation therapy (ADT) or ADT plus RLT. For patients allocated to ADT+RLT group, RP was recommended with priority, while RT was administrated to those refused RP and those with unresectable primary tumor after 1-3 months induced ADT. The primary outcome was radiographic progression-free survival (rPFS) and the secondary outcome was overall survival (OS). RESULTS: A total of 200 patients were enrolled between Sept 1, 2015 and Mar 10, 2019. The median age was 68 years and the median PSA at diagnosis was 98.8 ng/ml. Bone metastases and distant lymph node metastases exited in 96% and 15% of all patients. 96 of 100 patients in ADT+RLT group received RLT including 85 RP and 11 RT. After a median follow-up of 28 months, radiographic progression was observed in 19 of 100 patients in ADT+RLT group and 33 of 100 patients in ADT group. The median rPFS was not reached in ADT+RLT group and 50 months in ADT group (HR=0.50; 95% CI, 0.28 to 0.87; p=0.015). RLT related complications occurred in 24 of 85 RP patients (including 3 grade 3-4 complications) and 5 of 11 RT patients. In order to evaluate the OS, longer follow-up period is required. CONCLUSIONS: Local therapy to the primary tumor improves rPFS in patients with newly diagnosed, oligo-metastatic prostate cancer. Source of Funding: This study was supported in part by a grant from National Key R&D Program of China (No. 2017YFC0114303), a grant from the Natural Science Foundation of Shanghai Municipality (No. 16ZR1406500), a grant from the Guide Project of Science and Technology Commission of Shanghai Municipality (No.17411963100) © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e416-e416 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Bo Dai More articles by this author Junyu Zhang More articles by this author Sheng Zhang More articles by this author Hongkai Wang More articles by this author Qifeng Wang More articles by this author Yunyi Kong More articles by this author Yao Zhu More articles by this author Xiaojian Qin More articles by this author Guowen Lin More articles by this author Dingwei Ye More articles by this author Expand All Advertisement Loading ...

Assessing the safety and feasibility of metastasis-directed radiation and neoadjuvant hormone and radiation therapy followed by radical prostatectomy for treating oligometastatic prostate cancer: protocol for an open-label, dose-escalation, single-centre phase I clinical trial

Safety and Efficacy Study of Neoadjuvant Radiohormonal Therapy for Oligometastatic Prostate Cancer: Protocol of an Open-Label, Dose-Escalation, Single-Centre Phase I/II Clinical Trial

Protocol for Evaluating the Efficacy and Safety of Radiotherapy for Prostate and Oligometastatic Lesions in Patients With Low-Burden Sensitive Oligometastatic Prostate Cancer: An Open, Exploratory Pilot Clinical Trial

Multi-Center, Randomized, Controlled, Open-Label Effectiveness Study Of Primary Tumor Resection Or Not In Asymptomatic Colorectal Cancer With Unresectable Metastatic Disease.

618MO Local therapy to the primary tumour for newly diagnosed, oligo-metastatic prostate cancer: A prospective randomized, phase II, open-label trial

MP24-11 LOCAL THERAPY TO THE PRIMARY TUMOR FOR NEWLY DIAGNOSED, OLIGO-METASTATIC PROSTATE CANCER: A PROSPECTIVE RANDOMIZED, PHASE 2, OPEN-LABEL TRIAL

Multisite Radiotherapy Combined With Tislelizumab for Metastatic Castration-Resistant Prostate Cancer With Second-Line and Above Therapy Failure: Study Protocol for an Open-Label, Single-Arm, Phase Ib/II Study

A phase 2 single-arm study testing SBRT, adenosine signaling modulation, and immune checkpoint inhibition for men with hormone-sensitive oligometastatic prostate cancer (SBRT-AMICO).

Combination of Androgen Deprivation Therapy with Radical Local Therapy Versus Androgen Deprivation Therapy Alone for Newly Diagnosed Oligometastatic Prostate Cancer: A Phase II Randomized Controlled Trial

290P Initial Outcome of Definitive Intensity Modulated RT in Treatment of Bone Oligometastatic Prostate Cancer

Initial Outcome of Definitive Intensity Modulated Radiation Therapy in Treatment of Bone Oligometastatic Prostate Cancer

Radiotherapy of all metastatic lesions in metachronous oligometastatic prostate cancer

Prostate-Specific Membrane Antigen PET/CT-Guided, Metastasis-Directed Radiotherapy for Oligometastatic Castration-Resistant Prostate Cancer

Randomized phase II trial in prostate cancer with hormone-sensitive OligometaSTatic relapse: Combining stereotactic ablative radiotherapy and durvalumab (POSTCARD GETUG P13): Study protocol

A phase IIa study of sequential ("first strike, second strike") therapies, modeled on evolutionary dynamics of anthropocene extinctions, for high-risk metastatic castration-sensitive prostate cancer.

Analysis of adverse events after radiotherapy for primary and metastatic prostate carcinoma in patients with oligometastasized castration resistant prostate carcinoma

Systemic and tumor-directed therapy for oligometastatic prostate cancer (SOLAR): A phase II trial for veterans with de novo oligometastatic prostate cancer.

Efficacy of Neoadjuvant Chemohormonal Therapy in Oligometastatic Hormone-Sensitive Prostate Cancer: A Prospective, Three-Arm, Comparative Propensity Score Match Analysis

A Phase II Exploratory Trial of Adebrelimab in Combination with Chemotherapy and Concurrent Radiotherapy As a First-Line Treatment for Oligo-Metastatic Extensive-Stage Small-Cell Lung Cancer.

A Phase II Trial of Stereotactic Body Radiation Therapy and Androgen Deprivation for Oligometastases in Prostate Cancer (SBRT-SG 05)

Phase 1 Trial of Stereotactic Body Radiation Therapy Neoadjuvant to Radical Prostatectomy for Patients With High-Risk Prostate Cancer